Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SALUTE-D: Ranibizumab Regimens for DME
NCT02262260Phase 3Completed
- Sponsor
- Novartis
- Start
- Dec 2014
- Primary completion
- Sep 2017
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ranibizumab in diabetic macular edema (DME) (2 arms), sponsored by Novartis. Primary endpoint: Mean Change in Best-corrected Visual Acuity at 12 months. Started Dec 2014; status: completed.
02
Drugs
ranibizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT02262260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02262260.